Voisin Consulting Life Sciences publication icon
PublicationEMA

Hybrid or Mixed Marketing Authorization Application in the EU: not a trivial decision in new development programs for established drugs

Post thumbnail Hybrid or Mixed Marketing Authorization Application in the EU: not a trivial decision in new development programs for established drugs

For any medicinal product Marketing Authorization Application (MAA) in the European Union, the applicant needs to indicate the legal basis for the application. This legal basis, laid down in Directive 2001/83/EC as amended, determines the dossier content, the market exclusivity, and the pediatric requirements in a significant way.

Andreas Vogel
Hybrid or Mixed Marketing Authorization Application in the EU: not a trivial decision in new development programs for established drugs

2012 – Drug Information Journal

Voisin Consulting Life Sciences download icon

Download the full publication now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    publication by

    Andreas Vogel thumbnail
    Andreas Vogel
    Director Drugs and Biologics

    Voisin Consulting Life Sciences widget icon All our resources

    all our Resources

    More resources

    Voisin Consulting Life Sciences
    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.